

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

BAYER HEALTHCARE LLC AND BAYER)
HEALTHCARE PHARMACEUTICALS INC.,)

Plaintiffs,)

v.)

TEVA PHARMACEUTICALS USA, INC.,)
APOTEX CORP. and APOTEX, INC.)

Defendants.)

C.A. No. 16-1221 (LPS)

**DEFENDANTS’ NOTICE OF DEPOSITION TO
PLAINTIFFS BAYER HEALTHCARE LLC and BAYER HEALTHCARE
PHARMACEUTICALS INC. PURSUANT TO FED. R. CIV. P. 30(b)(6)**

TO ALL PARTIES AND THEIR ATTORNEYS OF RECORD:

PLEASE TAKE NOTICE that, pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure and the applicable Local Civil Rules of the United States District Court for the District of Delaware, Defendant Apotex Corp.; and Apotex, Inc. (collectively, “Defendants” or “Apotex”), by and through their attorneys, will take depositions upon oral examination of Plaintiffs Bayer Healthcare LLC and Bayer Healthcare Pharmaceuticals Inc. (collectively, “Plaintiffs” or “Bayer”) at a mutually agreed upon date and time by the parties and continuing from day to day thereafter until completed. The depositions will be conducted before an officer authorized by law to administer oaths and will be recorded by stenographic, sound, video, audiovisual, and/or any other appropriate means. The depositions will be taken for the purposes of discovery, for use at trial in these actions, and for any purposes permitted under the Federal Rules of Civil Procedure. You are invited to attend and participate.

Pursuant to Fed. R. Civ. P. 30(b)(6), Bayer shall designate one or more knowledgeable persons to testify on its behalf with respect to the matters set forth in Schedule A attached hereto, and the person(s) so designated shall be required to testify as to those matters known or reasonably available to Bayer. Bayer shall identify in writing each deponent who shall be designated to testify on its behalf at least ten (10) business days in advance of the deposition, including which portion(s) of this Notice each deponent is prepared to address.

Dated: November 1, 2018

/s/ Kenneth L. Dorsney
Kenneth L. Dorsney (#3726)
MORRIS JAMES LLP
500 Delaware Avenue, Suite 1500
Wilmington, DE 19801-1494
(302) 888-6800
kdorsney@morrisjames.com

Stephen R. Auten
Richard T. Ruzich
Ian Scott
Philip Y. Kouyoumdjian
Taft Stettinius & Hollister LLP
111 East Wacker Drive, Suite 2800
Chicago, IL 60601
312-527-4000
sauten@taftlaw.com
rruzich@taftlaw.com
iscott@taftlaw.com
pkouyoumdjian@taftlaw.com

*Attorneys for Defendants
Apotex Inc. and Apotex Corp.*

Schedule A

SCHEDULE A

DEFINITIONS AND INSTRUCTIONS

Defendants hereby incorporate by reference, as though fully set forth herein, the Definitions set forth in Defendants' First Set of Interrogatories (Nos. 1-6) and First Set of Requests for Production (Nos. 1-89).

DEPOSITION TOPICS

1. The conception, development, and reduction to practice of the subject matter of the asserted claims of the patents in suit.
2. Investigations, evaluations, analyses, studies, reports, and tests conducted by or on behalf of Bayer or received from Onyx involving, underlying, or concerning the following:
 - A. Communication dated December 28, 2011, from the European Examining Division. *See* BAYER_STIVARGA_01088635-36.
 - B. Response dated July 4, 2012. *See* BAYER_STIVARGA_01088653-54.
3. The preparation, filing, and prosecution of the patents-in-suit and any related application, including the identification of persons and other entities involved during such prosecution, any third-party observations submitted, any declarations submitted on behalf of Bayer or the inventors, and the earliest claimed priority date for each claim of the patents-in-suit asserted in the present litigations.
4. Data and information used as the basis for the statements made in the patents-in-suit (including all examples and tables) and during prosecution with the USPTO of the applications that led to the patents-in-suit and related applications, including but not limited to all facts, data, results, testing, experimental conditions, or protocols.

5. The preparation, filing, and prosecution of European Patent Application No. 07 818 583.2-2101 (the “2101 application”) and any related application, the identification of persons and other entities involved during such prosecution, any third-party observations submitted, and any declarations submitted on behalf of Bayer or the inventors.

6. Data and information used as the basis for the statements made in the 2101 application, including but not limited to the Communication dated December 28, 2011, BAYER_STIVARGA_01088635-36, and the Response dated July 4, 2012, BAYER_STIVARGA_01088653-54. and all examples and tables referred to in the application and during prosecution with the European Patent Office of the applications that led to WO 2008/043446 and related applications, including but not limited to all facts, data, results, testing, experimental conditions, or protocols.

7. The first synthesis of regorafenib and regorafenib with a physiologically acceptable carrier, including when, how, and by whom the synthesis occurred.

8. The preclinical and clinical studies identified in NDA No. 203085.

9. The basis for the selection of the particular cell lines identified in the Biological Example at columns 18 to 20 of the ’124 patent.

10. Any licenses, settlement agreements and other contracts between Bayer and Onyx concerning the patents-in-suit, including negotiations, attempts to license, or offers to license one or more of the patents or any product embodying any of the claims of one or more of the patents.

11. The basis for the selection of regorafenib for further development efforts, including but not limited to the experimental data concerning the safety and efficacy of regorafenib relative to other compounds considered or relied upon in support of that decision(s).

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.